Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02358889 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

A Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Iconic Therapeutics.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT02358889 is a Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization that has completed, run by Iconic Therapeutics. The registered enrollment target is 88 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02358889, a Phase 2 study of Age-related Macular Degeneration and Choroidal Neovascularization, has completed, sponsored by Iconic Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Conditions Studied

Age-related Macular Degeneration Choroidal Neovascularization

Interventions

  • OTHER Sham injection
  • BIOLOGICAL hI-con1
  • BIOLOGICAL ranibizumab

Study Locations (20)

California

  • - Arcadia
  • - Beverly Hills
  • - Campbell
  • - Glendale
  • - Laguna Hills
  • - Mountain View
  • - Palm Desert
  • - Palo Alto
  • - San Francisco
  • - Santa Ana

Florida

  • - Boynton Beach
  • - Fort Myers
  • - Panama City
  • - Sarasota
  • - Stuart
  • - Winter Haven

Arizona

  • - Phoenix
  • - Phoenix

Colorado

  • - Golden

Georgia

  • - Augusta

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2015-02
Est. Completion 2016-09
Phase Phase 2

Sponsor

Iconic Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02358889

The ClinicalTrials.gov registry entry for NCT02358889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (94% lower). The listed sponsor is Iconic Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Sham injection is the first listed.

NCT02358889 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02358889 about?

NCT02358889 is a clinical study titled "Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration". The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal n...

What is the current status of trial NCT02358889?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2015-02. Estimated completion is 2016-09.

What conditions does trial NCT02358889 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Choroidal Neovascularization.

What interventions are being tested in trial NCT02358889?

The interventions under investigation include: Sham injection (OTHER), hI-con1 (BIOLOGICAL), ranibizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02358889?

This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02358889 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Age-related Macular Degeneration

All registered trials for this condition

Choroidal Neovascularization

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.